https://www.selleckchem.com/pr....oducts/Cisplatin.htm
Half of those who received prior VEGFR therapy achieved SD (4/8). At median follow up of 7.9months, median PFS was 3.2months (95%CI, 1.8-3.9). N=1 required dose adjustment; N=1 came off drug for toxicity. There were no grade 3-4 adverse events. NOTCH1 and PI3K pathway alterations were most frequent. Low MYB protein expression was associated with longer duration of stability on ATRA (P0.01). While the trial did not meet its prespecified response endpoint, ATRA alone or in combination may be a low toxicity treatment for disease grow
Like
Comment
Share
